Glioblastoma Multiforme Gbm clinical trials

Explore recruiting glioblastoma multiforme gbm clinical trials.

Recruiting glioblastoma multiforme gbm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Glioblastoma Multiforme Gbm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-α2 gene previously administered to patients with glioblastoma multiforme

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma

Austria, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Itraconazole (ITRA) with standard radiotherapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM) ITRA-RAD: Phase I Clinical Study

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Patients with newly diagnosed Glioblastoma Multiforme (GBM). (PIRG)

Poland

Therapeutic use (Phase IV) EU CTIS Study details

A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors

Netherlands, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Glioblastoma Multiforme Gbm trials by city

Glioblastoma Multiforme Gbm in Toronto Glioblastoma Multiforme Gbm in Vancouver Glioblastoma Multiforme Gbm in Montreal Glioblastoma Multiforme Gbm in Calgary Glioblastoma Multiforme Gbm in Edmonton Glioblastoma Multiforme Gbm in Ottawa Glioblastoma Multiforme Gbm in Winnipeg Glioblastoma Multiforme Gbm in Quebec City Glioblastoma Multiforme Gbm in Hamilton Glioblastoma Multiforme Gbm in Kitchener Glioblastoma Multiforme Gbm in London Glioblastoma Multiforme Gbm in Halifax Glioblastoma Multiforme Gbm in New York Glioblastoma Multiforme Gbm in Los Angeles Glioblastoma Multiforme Gbm in Chicago Glioblastoma Multiforme Gbm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease